1. Авдошин В.П., Андрюхин М.И., Ольшанская Е.В. Оценка эффективности препарата Трометамола композитума в комплексном лечении больных уратным уролитиазом. Урология. 2008; 2: 8–10.
2. Авдошин В.П., Андрюхин М.И., Ольшанская Е.В. Парентеральная литолитическая терапия уратного уролитиаза. Урология. 2008; 4: 8–11.
3. Бутров А.В., Мороз В.А., Пожидаев Э.В.. Основные подходы к терапии КОС крови при диабетическом кетоацидозе. Трудн. пациент. 2007; 5 (12–13): 29–33.
4. Буланова О.Н., Золотокрылина Е.С., Закс И.О., Трубина И.Е. Кислородный бюджет, кислотно-щелочное равновесие в терминальных состояниях. Основы реаниматологии. Под ред. В.А.Неговского. М.: Медицина, 1975.
5. Бондарев А.А., Бутров А.В. Принципы терапии метаболического ацидоза при острой кровопотере. Трудн. пациент. 2008; 12.
6. Герасимов Л.В., Мороз В.В. Водно-электролитный и кислотно-основной баланс у больных в критических состояниях. Общ. реаниматол. 2008; 4 (4): 79–85.
7. Горовенко Н.Г. и др. Использование инфузионных препаратов для коррекции метаболического ацидоза. Укр. химиотерапевтич. журн. 2008; 1–2 (22): 29–33.
8. Дементьева И.И. Лабораторная диагностика и клиническая оценка нарушений гомеостаза у больных в критическом состоянии. М., 2007.
9. Зильбер А.П. Медицина критических состояний: общие проблемы. Петрозаводск: ПГУ, 1995.
10. Закс И.О., Лобус Т.В., Мороз В.В. Ощелачивающая терапия при сердечно-легочной реанимации: современные возможности. Реаниматол. Интенсивн. тер. Анестезиол. 1999; 4: 3–10.
11. Рябов Г.А. Синдромы критических состояний. М.: Медицина, 1994.
12. Салтанов А.И., Обухова О.А. Каковы альтернативы использования бикарбоната натрия при ацидозе? Вестн. интенсив. тер. 2009; с. 67–72.
13. Adrogue HG, Medias NE. Management of life-threatening acid-base disorders. N Engl J Med 1998; 338 (1): 26–34.
14. Filley GF, Kindig NB. Carbicarb, an alkalinizig iongenerating agent of possible usefulness. Trans Am Clin Climatol Assoc 1984; 96: 141–53.
15. Nahas GG. Use of an organic carbon dioxide buffer in vivo. Science 1959; 129: 782–3.
16. Nahas GG. The pharmacology of THAM (hydroxymethyl aminomethane). Pharmacol Rev 1962; 14: 447–72.
17. Nahas GG et al. Guidelines for the treatment of acidaemia with THAM. Drugs 1998; 55 (4): 517.
18. Rhee KH, Toro LO, McDonald GG et al. Carbicarb, sodium bicarbonate, and sodium chloride in hypoxic lactic acidosis. Effects on arterial blood gases, lactate concentrations, hemodynamic variables, and myocardial intracellular pH. Chest 1993; 104 (3): 913–8.
19. Brinkman GL. The use of THAM to prevent hyperventilation and acidosis while breathing carbon dioxide. Am J Med Sci 1960; 239: 728–31.
20. Wiklund L, Oquis L, Skoog G et al. Clinical buffering of metabolic acidosis: problems and solution. Resuscitation 1985; 12 (4): 279–93.
21. Brasch H, Iven H. Pharmacokinetics of TRIS (hydroxyrnethyl-)aminomethane in the rabbit. Arch Int Pharmacodyn Ther 1981; 254 (1): 4–12.
22. Holmdahl MH, Wiklund L, Wetterberg T et al. The place of THAM in the management of acidemia in clinical practice. Acta Anaesthesiol Scand 2000; 44: 524–7.
23. Martindale – the complete drug reference. Trometamol. 33 ed. London: Pharmaceutical Press, 2002.
24. Zaharko DS. The stimulation of insulin secretion in dogs by tris (hydroxymethyl) aminomethane. Proc Soc Exp Biol Med 1968; 129 (3): 812–7.
25. Wolf A, Levi L, Marmarovi A et al. Effect of THAM upon outcome in severe head injury: a randomized prospective clinical trial. Neurosurg 1993; 78: 54–5.
26. Fermon C. Buffer capacity of THAM. Use in cardioplegia in Guidelines for the treatment of acidemia with THAM. Drugs 1998; 55: 194–6.
27. Berman LВ, O'Connor TF, Nahas GG, Luchsinger PC. The renal effects of THAM in man. Physiologist 1959; 3 (10).
28. Brown ES, Bennett ТВ, Bunnell LL et al. Effects of THAM during CO2 breathing in man: ventilation and CO2 exchange. Physiologist 1959; 3 (18).
29. Clark LC Jr. Discussion of paper by Nahas, G. G. el al.: Transfusion acidosis and its correction with THAM. Trans Am Soc Artii Intern Organs 1960; 6: 253.
30. Clark LC Jr. The use of amine buffers in cardiovascular surgery. Ann N Y Acad Sci 1961; 92: 687–704.
31. Israels S. Discussion of paper by Strauss J et al. Effects of 2-ammo-2-hydroxymethyH., 3~propanedioi on renal function in reference to salicylate and glucose. Ann N Y Acad Sci 1961; 92: 593–5.
32. Kaplan S, Fox RP, Clark LC. Amine buffers in the management of acidosis: Study of respiratory and mixed acidosis. Am J Dis Child 1962; 103: 4–9.
33. Luchsinger PC, Berman LB. Carbon dioxide buffering in pulmonary disease. Clin Res 1960; 8: 255.
34. Manfredi F, Sieker SO, Spoto AP, Saltzman HA. Severe carbon dioxide intoxication. J Am Rned Ass 1960; 173: 999–1003.
35. O”Connor TF, Luchsinger PC, Nahas GG, Berman LВ. The respiratory effects of THAM in man. Physiologist 1959; 3 (92).
36. Peibce EC. II: Effects of 2-ammo-2~hydroxymethyl-l,3-propanediol (Tris) during cardiac bypass procedures. Ann N Y Acad Sci 1961; 92: 765–83.
37. Rees SВ, Youngbr MD, Freedlbnder AE. Some in vivo and in vilro observations on the effects of tris (hydroxy methyl)aminomei;hane in diabetic acidosis. Ann N Y Acad Sci 1961; 92: 755–65.
38. Samiy AH, Ramsay AG, Rees SB, Merrill JP. The use of 2-amino-2-hydroxymethyl-1,3-pro-panediol in the management of renal acidosis. Ann N Y Acad Sci 1961; 92: 802–12.
39. Samiy AH, Rees SВ, Younger MD et al. The use of tris buffer in the management of diabetic acidosis. IVе Congres de la Federation Internationale du Diabete; Geneva, Proceedings, III, 1961.
40. Sieker HO, Merwarth CR, Saltzman HA, Manfredi F. The use of 2-amino-2-hydroxymethyl-1,3-propanediol in severe carbon dioxide intoxication. Ann N Y Acad Sci 1961; 92: 783–94.
41. Swanson AG. Potential harmful effects of treating pulmonary encephalopathy with a carbon dioxide buffering agent. Am J Med Sci 1960; 240: 433–7.
42. Pfenninger E, Lindner KH, Ahnefeld FW. An infusion of THAM (trishydroxymethylaminomethane) as therapy to lower increased intracranial pressure in acute craniocerebral injuries. Anaesthesist 1989; 38 (4): 189–92.
43. Kallet RH et al. The Treatment of Acidosis in Acute Lung Injury with Tris-Hydroxymethyl Aminomethane (THAM). Am J Respir Crit Care Med 2000; 161 (4): 1149–53.
44. Hoste EA, Colpaert K, Vanholder RC et al. Sodium bicarbonate versus THAM in ICU patients with mild metabolic acidosis. J Nephrol 2005; 18 (3): 303–7.
45. Wolf A, Levi L, Marmarou A et al. Effects of THAM upon outcome in severe head injury: a randomized prospective clinical trial. Neurosurg 1993; 78: 54–9.